Skip to main content
S&P 5007,696.02+1.68%DOW53,421.58+3.16%NASDAQ25,762.53+1.54%BTC$80,148.00+3.09%ETH$2,418.41+5.72%GOLD$4,077.00+3.47%OIL$88.57-7.83%
Smart Investors Daily
SID Premium
RG

AMEX · RGNT

Regentis Biomaterials Ltd.

Healthcare · Medical - Instruments & Supplies

$1.37

Up+$0.00 (+0.00%)

Updated Nov 4, 2026, 8:39 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
28.11M
P/E ratio
—
Dividend yield
—
52-week range
$1.23 – $15.50
Volume
8.58K
Avg. volume
87.68K

Price performance · RGNT

RGNT price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

RGNT closed at $1.37 after 21 trading sessions, down 16.97% for the selected period.

Last close
$1.37
Period change
-16.97%
Period low
$1.23
Period high
$1.70
Daily close
View OHLC price history
RGNT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$1.36$1.43$1.34$1.378.58K
Nov 2, 2026$1.36$1.44$1.36$1.3715.3K
Oct 30, 2026$1.42$1.42$1.31$1.3724.87K
Oct 29, 2026$1.28$1.47$1.265$1.3661.9K
Oct 28, 2026$1.2601$1.30$1.23$1.2317.65K
Oct 27, 2026$1.27$1.415$1.25$1.2927.1K
Oct 26, 2026$1.30$1.32$1.26$1.2625.2K
Oct 23, 2026$1.42$1.42$1.28$1.2818.7K
Oct 22, 2026$1.48$1.48$1.40$1.4050.68K
Oct 21, 2026$1.51$1.5585$1.4843$1.4914.16K
Oct 20, 2026$1.53$1.54$1.47$1.4713.76K
Oct 19, 2026$1.44$1.60$1.44$1.4836.15K
Oct 16, 2026$1.60$1.60$1.46$1.4923.52K
Oct 15, 2026$1.55$1.56$1.5001$1.5514.77K
Oct 14, 2026$1.65$1.65$1.45$1.51133.46K
Oct 13, 2026$1.63$1.67$1.59$1.62533.51K
Oct 12, 2026$1.62$1.645$1.60$1.6336.34K
Oct 9, 2026$1.67$1.7398$1.60$1.6022.21K
Oct 8, 2026$1.69$1.73$1.65$1.70173.96K
Oct 7, 2026$1.64$1.69$1.63$1.6316.99K
Oct 6, 2026$1.67$1.7397$1.65$1.6533.96K

Latest RGNT news

The latest Smart Investors Daily articles mentioning RGNT.

Stock researchCompany · Overview

RGNT research

Overview

Company profile and research snapshot.

Company profile

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate (a polymer involved in tissue engineering) and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 12, 2026

Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC(R) at 8th ICRS Summit in Portugal

Engagement with leading orthopedic surgeons and cartilage repair specialists highlights growing awareness of GelrinC's off-the-shelf regenerative technologyGelrinC is CE Mark approved in Europe, where Regentis is expanding its network of Centers of Excellence to support surgeon training and commercialization effortsEuropean clinical sites also support the Company's ongoing U. FDA pivotal Phase III trialHERZLIYA, ISRAEL / ACCESS Newswire / October 12, 2026 / .

Yahoo · Sep 18, 2026

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd.

AUSTIN, Texas, Sept. 18, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancem

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By